DYSPEPSIA MANAGEMENT

Helicobacter pylori and functional dyspepsia: review of previous studies and commentary on new data

F Bazzoli, L De Luca, P Pozzato, RM Zagari, S Fossi, L Ricciardiello, G Nicolini, D Berretti, E Roda

Many studies have attempted to prove a link between Helicobacter pylori infection and functional dyspepsia but the results have been conflicting. Several mechanisms have been postulated for how H pylori associated inflammation disturbs antral and duodenal function but no pathophysiological explanation of how H pylori may cause dyspeptic symptoms is presently available.

SUMMARY
Many studies have tried to show an increased prevalence of Helicobacter pylori in patients with functional dyspepsia but the results have been conflicting. Another way of evaluating the role of H pylori in functional dyspepsia is to consider symptom improvement after cure of the infection. Two overviews have stated that no firm conclusion can be drawn from existing studies. A meta-analysis showed symptom improvement in 140 of 192 (73%) patients who became H pylori negative compared with 112 of 249 (45%) of those remaining H pylori positive. Furthermore, symptom improvement was more pronounced in patients in whom H pylori was eradicated. Differences in the rates of symptom improvement were found between studies with an observation period of less than, and those with an observation period of more than, 12 months. The duration of dyspeptic symptoms before H pylori eradication has also been shown to be predictive of the response—the longer the history, the less likely a benefit from eradication treatment. More recently, studies designed to avoid weaknesses of earlier studies could not confirm a role for H pylori in functional dyspepsia. After one year there was no significant difference in dyspeptic symptoms between eradication and control groups. In a secondary analysis however treatment success was significantly higher in patients in whom gastritis had healed. Therefore, perhaps 12 months is not long enough to allow complete healing of gastritis and thereby observe symptom relief.

INTRODUCTION
The association between Helicobacter pylori infection and chronic superficial gastritis is well accepted, while the role of chronic gastric inflammation in causing dyspeptic symptoms is controversial. After ruling out symptoms that may cause dyspeptic symptoms is presently available.

Dyspeptic symptoms were reported by 44% of the evaluated population (total: 1533 inhabitants). The prevalence of H pylori infection, evaluated using the 13C urea breath test, was 72% (n=1103) in individuals reporting dyspeptic symptoms and 64% (n=981) in the asymptomatic population (p<0.005). The prevalence of H pylori infection was significantly higher in dyspeptic than in asymptomatic individuals, even after excluding those with a history of peptic ulcer disease (gastric ulcer, n=36 (2.3%); duodenal ulcer, n=148 (9.6%)). Epigastric pain and heartburn were the symptoms most frequently associated with H pylori infection while the prevalence of infection in those reporting postprandial fullness was similar to that in asymptomatic individuals. These results however could be biased by the high prevalence of H pylori infection in the evaluated population and need further confirmation by excluding the presence of organic lesions by endoscopy.

In a meta-analysis, data showed that the prevalence of H pylori infection was greater in...
patients with dyspepsia than in controls, with a rate difference of 23% (95% confidence interval (CI) 13–32%) and an odds ratio of 2.3 (95% CI 1.9–2.7). Although the results of this meta-analysis seem to support the role of *H pylori* infection in the pathogenesis of dyspepsia, it appears that some of the studies considered are biased by the selection of controls not properly matched for age, socioeconomic status, and ethnic background—all known risk factors for *H pylori* infection.

**DO SYMPTOMS IMPROVE AFTER *H PYLORI* ERADICATION?**

Another possibility for evaluating the role of *H pylori* in functional dyspepsia is to consider symptom improvement resulting from cure of both the infection and associated inflammation of the gastric mucosa after eradication treatment. Functional dyspepsia treatment trials, due to suboptimal design or unclear presentation of data, have rarely been able to provide unequivocal evidence of the efficacy of a given treatment. Based on a systematic overview of published studies, Veldhuyzen van Zanten *et al* evaluated drug treatment of patients with functional dyspepsia (including *H pylori* positive individuals) and provided guidelines for future trials. Fifty two eligible studies were evaluated but many suffered from important weaknesses in design and execution. Only five studies used previously validated outcome measures. In the 52 studies, the placebo response ranged from 13% (4/32) to 73% (44/60). None of the trials provided unequivocal evidence for an efficacious therapy for the treatment of functional dyspepsia.

Trials of *H pylori* eradication and functional dyspepsia have also suffered from many methodological problems, and two systematic overviews have stated that no firm conclusion can be drawn from existing studies. The main issues addressed were discrepancy in the symptoms evaluated, the way in which severity of symptoms was assessed, lack of quality of life assessment, and consensus on outcome measures. Of the 16 trials included in the analysis by Talley, eight indicated that *H pylori* eradication treatment had a beneficial effect on functional dyspepsia but the other eight studies did not show any important benefit. Methodological weaknesses probably also accounted for the observed discrepancy. The main limitations included non-randomised, non-placebo controlled designs, lack of maintenance of blindedness, lack of an adequate definition of dyspepsia, inclusion of patients with gastroesophageal reflux disease, failure to measure compliance, lack of follow up after *H pylori* eradication, lack of an intention to treat analysis, and small sample size.

Another meta-analysis of studies on *H pylori* eradication in functional dyspepsia has been published by Laheij and colleagues. This study, although explicitly acknowledging the limited quality of the literature in this area, was able to show symptom improvement after eradication treatment in 73% of patients who became *H pylori* negative and 45% of patients who remained *H pylori* positive. Eradication of *H pylori* failed, symptoms only improved over a short period. In addition, symptom improvement was more pronounced in dyspeptic patients in whom *H pylori* was eradicated than in those in whom infection persisted. In this analysis, the authors evaluated 10 of 34 potentially eligible studies, including abstracts and letters to the editor (34 studies met inclusion criteria but 24 did not provide sufficient information to calculate the rates of improvement). Moreover, some papers showed a difference in symptom improvement in studies in which the period of observation was less than 12 months compared with studies in which follow up was for more than 12 months.

In the study by McCarthy *et al*, although not randomised and not double blinded, the mean symptom scores one year after eradication therapy were significantly higher in patients with persistent *H pylori* infection than in those remaining clear of infection. *Gut* Gilvarry *et al* have shown that patients treated with colloidal bismuth subcitrate, metronidazole, and tetracycline for seven days, and in whom *H pylori* was eradicated (85%, n=42), had an initial overall symptom score of 14.2, which decreased significantly at eight weeks to 11.5, at six months to 7.5, and at one year to 9.2 (p<0.01). When symptom subgroups were considered, improvement was significant at all times in the ulcer-like dyspepsia group but only at six months in the reflux-like and motility-like dyspepsia groups whereas there was no significant symptomatic improvement in the non-specific dyspepsia group.

More recently, results from a Scottish study by McColl *et al* showed that eradication of *H pylori* (using omeprazole, metronidazole, and amoxicillin for 14 days) produced resolution of dyspepsia in a significantly higher proportion of patients with functional dyspepsia compared with controls (21%, n=33, in the group receiving eradication therapy v 7%, n=11, in the group given omeprazole alone). The duration of dyspeptic symptoms before *H pylori* eradication therapy was shown to be predictive of the response; therefore, the longer the history of dyspepsia, the less likely there was to benefit from this treatment. It is probable that in patients with dyspeptic symptoms, *H pylori* associated gastritis determines the symptom changes, resulting in persistent dyspepsia despite eradication of the infection. Resolution of symptoms in this study, although significantly more frequent after *H pylori* eradication, was only about 20% and one could suggest that the high background prevalence of peptic ulcer disease in this population might have influenced the outcome of the trial.

In two other recent studies, designed particularly to avoid the weaknesses of the earlier studies, the beneficial effect of *H pylori* eradication in patients with functional dyspepsia has not been confirmed. In one of these studies, the eradication rate in the group treated with omeprazole, amoxicillin, and clarithromycin was 85% (n=113), and 4% (n=6) in the group treated with omeprazole and placebo antibiotics. One year after *H pylori* eradication there was no significant difference in the reduction of dyspeptic symptoms between the treatment groups (omeprazole group, 24.1% (95% CI, 17–32%); placebo group, 21.8% (95% CI, 15–30%)). Nevertheless, in a secondary analysis, it was found that treatment success was significantly higher in patients in whom gastritis had healed than in those in whom gastritis had not healed (32% (41/127) v 17% (24/144)).

### Table 1 Comparison of the characteristics of the studies by Gilvarry and colleagues and McColl and colleagues with those of the OCAY and ORCHID studies

<table>
<thead>
<tr>
<th>Studies by Gilvarry and colleagues and McColl and colleagues</th>
<th>OCAY and ORCHID studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single centre</td>
<td>Multicentre</td>
</tr>
<tr>
<td>Not generalisable</td>
<td>Generalisable</td>
</tr>
<tr>
<td>Peptic ulcers found in 14% at follow up</td>
<td>Peptic ulcers found in 2% at follow up</td>
</tr>
<tr>
<td>Baseline observation period: 3 and 6 months</td>
<td>Baseline observation period: 7 days</td>
</tr>
<tr>
<td>Symptom scores locally validated</td>
<td>Few patients in individual centres</td>
</tr>
<tr>
<td></td>
<td>Symptom questionnaires not validated in each centre</td>
</tr>
<tr>
<td></td>
<td>Symptom assessments more difficult in multinational studies</td>
</tr>
</tbody>
</table>

---

[Refs: H pylori, Talley, studies, methodological problems, symptoms, dyspepsia, *H pylori* eradication, improvements, meta-analyses, functional dyspepsia, symptom improvement, *H pylori* infection, abstracts, letters, McCarthy, 34 studies, 24 studies, Scottish study, McColl, treatment success, omeprazole, amoxicillin, clarithromycin, 85% eradication, 4% placebo, secondary analysis, gastritis, healed patients, not healed patients]
(21/123); p=0.005). Although the results of these two studies suggest that overall, eradication of *H pylori* does not relieve the symptoms of functional dyspepsia, one should consider that 12 months may not be enough time to allow complete healing of gastritis. Possibly, a longer follow up period could further increase the proportion of patients in whom symptoms improve following *H pylori* eradication.

Comparing the studies with different outcomes, one should consider that the studies by Gilvarry and colleagues and McColl and colleagues were both single centre studies and therefore their results are less generalisable and could be biased by population characteristics, such as the higher background prevalence of peptic ulcer disease (table 1). Indeed, peptic ulcers were found in 14% of patients at follow up. Nevertheless, in these studies, enrollment was based on baseline observation periods of three and six months, respectively, which provides more information about severity of symptoms. Furthermore, symptom scores were locally validated: the Glasgow dyspepsia severity score was used in the study by McColl and colleagues and a validated score (in house pilot study, unpublished data) was used in the study by Gilvarry and colleagues.

On the other hand, multicentre studies provide results that can be generalised and are less likely to be biased by local differences in the prevalence of peptic ulcer disease. In fact, peptic ulcers were found in only 2% of patients at follow up in the OCAY study. One could object that only a few patients were enrolled in each centre in the OCAY and ORCHID studies and are therefore not truly representative of the population. Furthermore, a “run in” period of seven days, which these studies used, might not be long enough to properly select eligible patients. However, the history of dyspepsia was 1–3 months. Finally, the performance of the multicentre trials could have been limited by the fact that symptom questionnaires were not locally validated, and it is well known that symptom assessment is more difficult in multinational studies, due to language problems and definitions of symptoms.

**CONCLUSION**

No pathophysiological explanation of how *H pylori* may cause dyspeptic symptoms is presently available. In contrast with peptic ulcer disease, *H pylori* has not been established as playing a definite role in functional dyspepsia. Well designed studies are now published but they provide conflicting results. Based on existing data, it appears that the maximum treatment efficacy to be expected from *H pylori* eradication in functional dyspepsia is about 20%. We need to learn more about the true relationship between symptoms and infection and determine whether there are identifiable risk factors for the onset of symptoms. Results of large studies are available but longer follow up periods are probably needed to determine if further healing of gastritis will result in more symptom relief.

**Authors’ affiliations**

F Bazzoli, L De Luca, P Pozzato, R M Zagari, S Fossi, L Ricciardiello, G Nicolini, D Berretti, E Roda, Department of Gastroenterology, Policlinico S Orsola, Bologna, Italy

Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The authors of this paper have received sponsorship for travel and an honorarium from AstraZeneca

**REFERENCES**

**Helicobacter pylori** and functional dyspepsia: review of previous studies and commentary on new data

F Bazzoli, L De Luca, P Pozzato, RM Zagari, S Fossi, L Ricciardiello, G Nicolini, D Berretti and E Roda

*Gut* 2002 50: iv33-iv35
doi: 10.1136/gut.50.suppl_4.iv33

Updated information and services can be found at:
http://gut.bmj.com/content/50/suppl_4/iv33

These include:

**References**
This article cites 13 articles, 1 of which you can access for free at:
http://gut.bmj.com/content/50/suppl_4/iv33#ref-list-1

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Dyspepsia (297)
- Campylobacter, Salmonella, Shigella, Escherichia coli (242)
- Helicobacter pylori (218)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/